CA2837174A1 - Cb-183,315 compositions and related methods - Google Patents

Cb-183,315 compositions and related methods Download PDF

Info

Publication number
CA2837174A1
CA2837174A1 CA2837174A CA2837174A CA2837174A1 CA 2837174 A1 CA2837174 A1 CA 2837174A1 CA 2837174 A CA2837174 A CA 2837174A CA 2837174 A CA2837174 A CA 2837174A CA 2837174 A1 CA2837174 A1 CA 2837174A1
Authority
CA
Canada
Prior art keywords
sucrose
solid
weight percent
formulations
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2837174A
Other languages
English (en)
French (fr)
Inventor
Sandra O'connor
Sophie Sun
Gaauri Naik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Publication of CA2837174A1 publication Critical patent/CA2837174A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2837174A 2011-05-26 2012-05-24 Cb-183,315 compositions and related methods Abandoned CA2837174A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490584P 2011-05-26 2011-05-26
US61/490,584 2011-05-26
PCT/US2012/039476 WO2012162567A1 (en) 2011-05-26 2012-05-24 Cb-183,315 compositions and related methods

Publications (1)

Publication Number Publication Date
CA2837174A1 true CA2837174A1 (en) 2012-11-29

Family

ID=46208839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837174A Abandoned CA2837174A1 (en) 2011-05-26 2012-05-24 Cb-183,315 compositions and related methods

Country Status (12)

Country Link
US (2) US20130109633A1 (enExample)
EP (1) EP2714012A1 (enExample)
JP (1) JP2014515371A (enExample)
KR (1) KR20140037877A (enExample)
CN (1) CN103687589A (enExample)
AR (1) AR086576A1 (enExample)
BR (1) BR112013030369A2 (enExample)
CA (1) CA2837174A1 (enExample)
MX (1) MX2013013760A (enExample)
RU (1) RU2013157188A (enExample)
TW (1) TW201300124A (enExample)
WO (1) WO2012162567A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173932A1 (en) * 2016-04-08 2017-10-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150224A0 (en) * 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides and pharmaceutical compositions containing the same
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
JP2004525108A (ja) * 2000-12-18 2004-08-19 キュービスト ファーマスーティカルズ インコーポレイテッド 精製リポペプチドの調製方法
RU2007121705A (ru) * 2004-11-12 2008-12-20 Кьюбист Фармасьютикалз Антиинфекционные липопептиды
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
NZ594019A (en) 2008-12-22 2013-08-30 Cubist Pharm Inc Novel antibacterial agents for the treatment of gram positive infections
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
CN102060914B (zh) * 2009-11-13 2014-09-17 华东理工大学 海洋芽孢杆菌b-9987产脂肽类化合物及其制备和应用
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US20110124551A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin

Also Published As

Publication number Publication date
BR112013030369A2 (pt) 2016-12-13
RU2013157188A (ru) 2015-07-10
CN103687589A (zh) 2014-03-26
KR20140037877A (ko) 2014-03-27
JP2014515371A (ja) 2014-06-30
TW201300124A (zh) 2013-01-01
WO2012162567A1 (en) 2012-11-29
AR086576A1 (es) 2014-01-08
MX2013013760A (es) 2014-01-08
US20130109633A1 (en) 2013-05-02
US20140135273A1 (en) 2014-05-15
EP2714012A1 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
KR930007251B1 (ko) 안정한 니코란딜 제제의 제조방법
US20090281136A1 (en) Prasugrel pharmaceutical formulations
US20190008774A1 (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
CN100446757C (zh) 未经制粒制备的包含阿伐他汀的药物组合物
KR20100015764A (ko) 프레가발린을 포함하는 안정한 약학적 조성물
EP2676660A1 (en) Compositions preventing hypertension comprising soluplus
US20220409701A1 (en) Process for producing a tablet comprising glp-1 peptides
CN101721410B (zh) 硫酸氢氯吡格雷的固体药物组合物
US20090292016A1 (en) Stable Pharmaceutical Compositions Containing Pravastatin
KR100760112B1 (ko) 아토르바스타틴의 제약 조성물
US20140135273A1 (en) Cb-183,314 compositions and related methods
EP4436554A1 (en) Pharmaceutical compositions comprising eltrombopag
JP2020090471A (ja) アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
EP2906203B1 (en) Effervescent cefdinir formulation
KR20140050876A (ko) 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도
AU2013346397B2 (en) A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
US10272131B2 (en) Linaclotide stable composition
JP2020090470A (ja) アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
CN101460191A (zh) 包含湿敏性药物的稳定制剂及其制备方法
TR202100250A2 (tr) Api̇ksaban i̇çeren fi̇lm kapli tablet
KR100653388B1 (ko) 안정성이 우수한 ａｃｅ 저해제를 포함하는 약제학적 조성물
GB2491205A (en) Composition comprising bosentan and diluents
AU2002314915A1 (en) Stable pharmaceutical compositions containing pravastatin
HK1213807B (en) A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180524